RxDoctor Payments Data

Adam Perlmutter, DO

Urology · Plymouth, INNPI 1235270067

Payments from drug & device makers

$4,463in general payments, 2019–2025

Across 243 payments — averaging $18.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$694
  • Johnson & Johnson$478
  • Sumitomo Pharma America, Inc.$324
  • Pfizer$296
  • Urogen Pharma, Inc.$258
  • Endo Pharmaceuticals Inc.$224
  • plus $2K from 39 others

What the payments were for

  • Food & beverage$4,10492%
  • Education$3608%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,463 in reported general payments places this provider in the 55th percentile of 272 urology providers in Indiana.

See all urology providers in Indiana

Medicare billing

Part B allowed, 2024
$345,805
Medicare patients
891
Services billed
7,629

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide56$789,956
ErleadaApalutamide35$518,826
MyrbetriqMirabegron264$229,431
OrgovyxRelugolix60$200,343
NubeqaDarolutamide12$167,068
GemtesaVibegron26$36,078
Solifenacin Succinate327$26,818
Mirabegron ErMirabegron29$23,327
Tamsulosin Hcl1,242$15,551
Oxybutynin Chloride ErOxybutynin Chloride388$10,836
Tolterodine Tartrate ErTolterodine Tartrate44$6,131
Testosterone27$5,749
Finasteride481$5,503
Alfuzosin Hcl ErAlfuzosin Hcl215$4,325
Imipramine Hcl117$2,941

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$694$1,019,387320 claims
Johnson & JohnsonErleada$478$518,82635 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$324$236,42186 claims
BayerNubeqa$63$167,06812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 272 urology providers in Indiana.

Other urology in Plymouth

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →